In: Nursing
1) ans)Cerebral Malaria is a symmetric and diffuse, potentially reversible encephalopathy caused mainly by P. falciparum.It is an error to considering that any cerebral clinical manifestation in a patient with malaria is defining the disease.The most agreed definition includes the confirmation of P. falciparum infection and the exclusion of other causes of encephalitis,since neurological symptoms can be mimicked by metabolic acidosis, anemia or hypoglycemia
If parasite-filled blood cells block small blood vessels to your brain (cerebral malaria), swelling of your brain or brain damage may occur. Cerebral malaria may cause seizures and coma. Breathing problems. Accumulated fluid in your lungs (pulmonary edema) can make it difficult to breathe
Cerebral malaria
In rare cases, malaria can affect the brain. This is known as cerebral malaria, which can cause your brain to swell, sometimes leading to permanent brain damage. It can also cause fits (seizures) or coma.
When patients are suffering from the most severe form of
malaria, known as cerebral malaria, infected red blood cells are
trapped within the microscopic vessels of the brain. This impedes
critical oxygen delivery, resulting in coma and often leading to
death
.
2) Ans)Severe malaria is defined as presence of Plasmodium falciparum parasitemia and one or more of the manifestations in the table (table 1). Most cases of severe malaria are attributable to Plasmodium falciparum (90 percent), but Plasmodium vivax and Plasmodium knowlesi can also cause severe disease
Other complications of a severe case of malaria can include:
breathing problems (such as fluid in your lungs)
liver failure and jaundice (a yellow discolouration of the skin)
shock (sudden drop in blood flow)
spontaneous bleeding.
abnormally low blood sugar.
kidney failure.
swelling and rupturing of the spleen.
dehydration
In adults, cerebral malaria is part of a multi-organ disease.
Patients develop fever, headache, body ache and progressively,
delirium and coma. Compared to African children, seizures
papilledema and retinal changes are less common and coma resolution
is slower
Treat adults and children with severe malaria (including infants, pregnant women in all trimesters and lactating women) with intravenous or intramuscular artesunate for at least 24 h and until they can tolerate oral medication. Once a patient has received at least 24 h of parenteral therapy and can tolerate oral therapy, complete treatment with 3 days of an ACT.
Strong recommendation, high-quality evidence
Researchers are working to create a vaccine against malaria. Vaccination is expected to become an important tool to prevent malaria in the future.
One way to prevent malaria is to avoid mosquito bites with the following strategies:
As much as possible, stay indoors in well-screened areas, especially at night when mosquitoes are most active.
Use mosquito nets and bed nets. It's best to treat the nets with the insect repellant permethrin.
Wear clothing that covers most of your body.
Use an insect repellent that contains DEET or picaridin. These repellents are applied directly to your skin, except around your mouth and eyes. If you choose a picaridin-based repellant, you will need to reapply it every several hours.
Apply permethrin to clothing.
It is strongly recommended that you take preventive medication when you travel to a region of the world that has malaria. Keep in mind that these medications can prevent most malaria infections, but travelers occasionally get malaria even when they are taking one of these drugs. If you develop an illness with fever within a year of your return, seek immediate medical attention and tell a health care professional about your travel.
Efficacy:
Treatment regimen differed depending on the study but consisted
essentially in IV AS (except for the use of rectal route in one
study),n first or second line (mostly after IV Quinine) alone or in
association with several anti-malarial drugs. In a vast majority of
cases, patients were treated for severe malaria
Preventing long-term sequelae, such as improving neurocognitive
outcomes in SM survivors, should be an important consideration when
it comes to potential adjunctive therapy; however so far, the
majority of attempts to enhance the efficacy of anti-malarial drugs
with adjunctive therapy have failed. The development of adjunctive
therapy would benefit from a more complete understanding of the
physiopathology of SM and CM, and how it differs between adults and
children. The identification of host biomarkers associated with
disease severity and host response to treatment could provide a
useful read out of therapeutic efficacy, and empower RCTs to
evaluate adjunctive therapy with smaller and better defined
cohorts.
Please Rate the answer ? thank you